The Philadelphia region's only hospital dedicated to the treatment of neurologic conditions
Jefferson Hospital for Neuroscience (JHN) is recognized as a leader in neurologic care and research. We offer a comprehensive range of services in neurologic subspecialties, including brain tumors, headache, epilepsy, multiple sclerosis, Parkinson's disease and other movement disorders, neurovascular diseases, cognitive impairment and Alzheimer's, spine and neuromuscular disorders.
Jefferson is recognized as one of the most advanced centers in the U.S. for stroke, and our patients have access to the latest endovascular procedures including thrombolytic therapy, endovascular coiling for aneurysm, cerebral angiography, embolization and carotid artery angioplasty/stenting. In addition, we are one of only 14 Model Spinal Cord Injury Centers in the country. Neurocritical care is a specialty that spans all those areas, and patients in acute situations benefit from being in a dedicated neurointensive care unit staffed by neurointensivists.
On a daily basis, our clinicians connect patients with state-of-the-art clinical trials that evaluate new therapies to treat disease or extend life. Jefferson doctors lead many of those clinical trials, sometimes collaborating with researchers in this country and abroad. Through the publication of scholarly articles, community-based research projects and a telemedicine consulting network for stroke, the reach of our specialists is vast.
To refer a patient to Jefferson, please call 215-503-8888 or fill out our online referral request form.
12 minutes is the average time from stroke consultation request to telemedicine response
1,100 surgeries performed annually for benign and malignant brain tumors
40 dedicated beds in our Neurointensive Care Unit
At Jefferson, we are continually improving patient outcomes by providing carefully coordinated and sequenced therapies and state-of-the-art treatments.
For example, Jefferson's telemedicine service connects JHN stroke specialists to emergency departments at outlying hospitals, which allows stroke patients throughout the Philadelphia region to benefit from state-of-the-art treatment. A preliminary analysis of outcomes data for the stroke network found that 97 percent of stroke patients who met the criteria for intravenous tissue plasminogen activator (IV tPA) went on to receive the therapy.
While preclinical evidence suggests that early decompression for spinal cord injury (SCI) improves neurologic outcome, many surgeons still take the traditional approach of waiting at least 24 hours before intervening. We evaluated the advantages of early-versus-later decompression for SCI in 313 patients and found that nearly 20 percent of patients who underwent early decompression had an improvement of 2 or more in their AIS score compared to 8.8 percent of the late decompression group. Complications occurred in 24.2 percent of the early surgery patients compared to 30.5 percent of the latter group.
JHN is actively shaping the future of neurosurgery and neurology through groundbreaking clinical research. New discoveries are made in Jefferson labs every day.
Jefferson University Hospitals
111 South 11th Street
Philadelphia, Pennsylvania 19107
Thomas Jefferson University Hospitals are dedicated to excellence in patient care, patient safety and the quality of the healthcare experience.
Thomas Jefferson University Hospitals have 969 licensed acute care beds, with major programs in a wide range of clinical specialties. Services are provided at five primary locations — Thomas Jefferson University Hospital (the main hospital facility, which was established in 1825) and Jefferson Hospital for Neuroscience, both in Center City Philadelphia; Jefferson's Methodist Hospital and Jefferson at the Navy Yard, both in South Philadelphia; and Jefferson at Voorhees in South Jersey.